These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 16103761

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES).
    Schrader J, Lüders S, Kulschewski A, Hammersen F, Plate K, Berger J, Zidek W, Dominiak P, Diener HC, MOSES Study Group.
    Stroke; 2005 Jun; 36(6):1218-26. PubMed ID: 15879332
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Cost-utility analysis of eprosartan compared to enalapril in primary prevention and nitrendipine in secondary prevention in Europe--the HEALTH model.
    Schwander B, Gradl B, Zöllner Y, Lindgren P, Diener HC, Lüders S, Schrader J, Villar FA, Greiner W, Jönsson B.
    Value Health; 2009 Sep; 12(6):857-71. PubMed ID: 19508663
    [Abstract] [Full Text] [Related]

  • 14. Eprosartan: a review of its use in the management of hypertension.
    Robins GW, Scott LJ.
    Drugs; 2005 Sep; 65(16):2355-77. PubMed ID: 16266204
    [Abstract] [Full Text] [Related]

  • 15. Eprosartan (Teveten) offers new opportunities to prevent a second stroke.
    Cardiovasc J S Afr; 2005 Sep; 16(1):56. PubMed ID: 15778775
    [No Abstract] [Full Text] [Related]

  • 16. [Effect of eprosartan on thrombocytes aggregative capacity in patients with arterial hypertension and metabolic syndrome].
    Simonenko VB, Medvedev IN, Kumova TA.
    Klin Med (Mosk); 2008 Sep; 86(4):19-21. PubMed ID: 18494280
    [Abstract] [Full Text] [Related]

  • 17. Clinical profile of eprosartan: a different angiotensin II receptor blocker.
    Blankestijn PJ, Rupp H.
    Cardiovasc Hematol Agents Med Chem; 2008 Oct; 6(4):253-7. PubMed ID: 18855637
    [Abstract] [Full Text] [Related]

  • 18. [Effect of antihypertensive drugs of various pharmacological groups on reaction of arterial pressure under conditions of stree testing. Part II. Value of various strategies of potentiation of systemic vasodilatation].
    Praskurnichiĭ EA, Shevchenko OP, Makarova SV, Zhukova VA, Savel'eva SA.
    Kardiologiia; 2008 Oct; 48(4):18-24. PubMed ID: 18447835
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.